OABI - OmniAb, Inc.
About OmniAb, Inc. (https://www.omniab.com)
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Matthew W. Foehr | President, Chief Executive Officer & Director | 1973 | $1,066,620 USD |
| Charles S. Berkman | Chief Legal Officer & Secretary | 1969 | $742,065 USD |
| Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer | 1968 | $730,741 USD |
| Bill Harriman | Senior Vice President of Antibody Discovery | – | – |
| Bob Chen | Senior Vice President of Discovery Systems | – | – |
| Christel Iffland | Senior Vice President of Antibody Technologies | – | – |
| Cia McCaffrey | Senior Vice President of People & Talent | – | – |
| Todd Pettingill | Vice President of Business Development & Strategy | – | – |
| Yasmina Noubia Abdiche | Senior Vice President of Exploratory Research | – | – |